Purpose: Powdered sevelamer carbonate is a new phosphate binder with unproven therapeutic benefit in Indian population. Hence, we aimed to compare its efficacy and safety with calcium acetate in patients with Chronic Renal Disease on hemodialysis. Methods: This was a randomized, prospective, cross over and open labeled study, conducted in the
INTRODUCTION:
Hyperphosphatemia is a debilitating consequence of chronic renal disease (CRD). Its long term complications are renal osteodystrophy, hyperparathyroidism, and increased cardiovascular calcification leading to increased mortality and morbidity [1] [2] [3] [4] . It can be controlled by restricting phosphorus in the diet, oral phosphate binders (PB) and dialysis. Dietary restriction on phosphate is possible only up to a limit before it adversely affects nitrogen balance. Dialysis can remove up to 70 % of ingested phosphorus 5 . Hence, for long term phosphorus control, patients are prescribed oral PBs. Until recently calcium based PBs were the main stay of treatment but upon including lifetime cost and quality adjusted life-years gained sevelamer may gain approval 6 .
Sevelamer carbonate is a non-metal oral PB also used to treat hyperphosphatemia. Its efficacy is proven in western population [6] [7] [8] . Unlike metal based oral PB, it is a cross linked polymer containing multiple amine groups. Its powdered form allows it to be sprinkled on food like salt before consumption, and may prove valuable for patients with difficulty swallowing or chewing. It binds to phosphorus in the food, making it unavailable for absorption. It is excreted in the feces. It is also shown to lower serum low density lipoprotein (LDL), triglyceride (TG), C-reactive protein (CRP) and lipids 8, 9 . C-reactive protein (CRP) is an acute phase reactant. However, when it is raised for prolonged periods of time it denotes arterial inflammation. Hence, raised CRP is a biomarker for sudden deaths in CRD patients [10] [11] [12] . Phosphate binders (PB) are used to control serum phosphorus. Powdered formulation has an advantage of mixing well with food before consumption, hence preventing absorption. In Indian population few studies have been done comparing sevelamer with calcium based PBs 13, 14 . However, these studies used hydrochloride form that has its own disadvantages. They were done over a short period in small patient population. Furthermore, there has been no study in India that has compared powdered form of sevelamer carbonate to calcium acetate. Hence, this study was designed to study the effect of powdered sevelamer carbonate with calcium acetate in patients with chronic renal disease on hemodialysis.
MATERIALS AND METHODS:
This was a prospective, open labeled, cross-over, comparative and randomized study, conducted in patients undergoing maintenance hemodialysis (for ≥6 weeks) in the Department of Nephrology, Christian Medical College (CMC) and Hospital, Ludhiana. The study was conducted after obtaining approval of the Institute Research Committee. The study design was explained to all the patients. All patients were provided with study information and written informed consent was obtained before any intervention.
Patients with chronic renal disease (CRD) of both genders, over 18 years of age, undergoing hemodialysis were included. Those with hypercalcaemia, severe GI disorder, any malignancy, breast feeding women and known hypersensitivity to phosphate binders were excluded.
Figure: 1 Study design
All patients were given a washout period of 1 week during which no PB was administered. At the end of 1 week all biochemical parameters were done. If the serum phosphorus level was greater than 4.5 mg/dl the patients was randomized in either group (A or B). Randomization was done according to a computer generated random number table. Group A patients were given powdered sevelamer carbonate in a dose of 400 mgs three times a day for the first 4 weeks (n= 25). They were asked to sprinkle it on food like salt and stir well. At the end of 4 weeks all biochemical parameters were repeated. This was followed by one week of washout period at the end of which all biochemical parameters repeated, followed by tablet calcium acetate (667mgs) three times a day for the next 4 weeks (n=25). At the end of 4 weeks all biochemical parameters were repeated again. The calcium acetate tablets were consumed with food or immediately after finishing the meal. The same procedure was repeated with group B patients but they were given tablet calcium acetate for the first 4 weeks followed by powdered sevelamer carbonate for the next 4 weeks. The biochemical parameters included serum phosphorus, calcium, LDL, TG, Cholesterol and CRP. All data was recorded in the patient particular sheet. Unpaired t-test was done to determine if there was a statistically significant difference in the biochemical values after both washouts in the two groups. Since this was insignificant (p=0.711), it was decided to combine pre drug data. At the end of the study, data of 50 patients (25+25) who had taken powdered sevelamer carbonate was collected, and done similarly for patients who had taken calcium acetate. The total duration of the study was 10 weeks. The study design is depicted in Figure1. Consort chart is given in Figure 2 . Figure: 2. Consort diagram.
Adverse Drug Reaction (ADR) recording was also done at every follow up and hemodialysis visit for each patient. Both the study drugs (powdered sevelamer carbonate and calcium acetate) along with the investigations were funded by Emcure Pharmaceutical Ltd., Pune, India. The patients did not bear any additional cost by participating in the study. The company had no role in the study design or evaluating the study results or the preparation of this manuscript.
Statistical analysis:
To compare Sevelamer carbonate group with Calcium acetate group, a sample of 100 patients was required (n=50 each group) to achieve 80% power. All statistical tests used for comparisons of the 2 treatment periods were 2 tailed, with probability value of less than 0.05 required for significance. Sample size was calculated using OpenEpi version 3.0.1. The values are expressed as mean ± SD (standard deviation). SPSS 21.0, Armonk NY: IBM corp. was used to analyze the data.
RESULTS
We screened 209 patients, out of which 159 were excluded: 154 due to low serum phosphorus after the washout period, 1 patient refused to participate, 3 patients had history of questionable compliance with medication and 1 patient had no requirement for phosphate binder.
Fifty patients who met the inclusion criteria were included in the study. Out of these 31 were men. The Figure 3 ) and calcium phosphorus product ( Figure 4 ) was significant in both the groups when compared to baseline (p<0.05). However, this significance was lost when comparison was made in-between the two groups (p>0.05). There was no significant change in calcium, LDL, TG, CRP level at 4 weeks and when comparison was made between groups A and B(p>0.05). The baseline and 4 week values are given in Table 2 . 
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Safety profile
In this study diarrhoea was the only adverse effect reported by two patients in group A. First patient was given de-challenge and a re-challenge. He reported diarrhoea again after re-challenge and was taken off the study. It was 8 on Naranjo's scale. Second patient in the same group also reported diarrhoea which was selflimiting. No adverse effects were reported in group B. In the current study both PB were equally safe since there was no hypercalcaemia seen in calcium acetate arm or hypocalcaemia seen in sevelamer carbonate arm.
DISCUSSION:
Both powdered sevelamer carbonate and calcium acetate were equally efficacious in reducing hyperphosphatemia in patients with chronic renal disease (CRD). Baseline demographic profile; age, gender and aetiology; were comparable in both groups. The mean age of patients in this study was similar to earlier studies done in India but lower than that of USA [11] [12] [13] . It strengthens the evidence that CRD affects younger population in India 16, 17 . In this study number of men was higher; although this disease is known to affect women more often than men. This trend is also observed in other studies in India 17, 18 The most common etiology of CRD reported from India is diabetic nephropathy followed closely by systemic hypertension; although in this study it was systemic hypertension. This data further adds to the need of studies that will elucidate age, gender distribution and etiology of CRD specifically for India.
In this study, serum phosphorus was lowered equally by both PB. There was no statistical difference when phosphorus lowering was compared in between the two groups. Various international studies comparing these PB in adult population have also deduced the findings of this study 19, 20 An Indian study also supports this finding although the cohort were pediatric population 13, 14 .
Reduction in calcium phosphorus product was significant in both groups although this significance was lost in intergroup analysis. This finding is supported by the Indian study done on pediatric age group 14 . It however, had limited sample size and was not done in adults. The same results were reflected in other international studies also done in both pediatric 20 and adult population 21 .
Although sevelamer has shown beneficial effects in lowering cholesterol, LDL, TG, current study did not show any significant reduction in either group. 22 It could perhaps be due to the short duration of the study. CRP is an acute phase reactant, elevated CRP levels are associated with increased cardiovascular mortality in CRD 23 . This study did not deduce significant reduction in CRP levels in either group. To the best of our knowledge, no study in Indian setup has compared CRP as primary or secondary outcome.
Safety: Both PBs were well tolerated as seen in other studis 24 although only one case of hypercalcaemia has been reported from a long term study 25 . In this study however, the adverse events were less as compared to these earlier studies. Both sevelamer carbonate and calcium acetate are well tolerated drugs.
CONCLUSION:
Hence, from the data of this study we conclude that powdered sevelamer carbonate does not reduce cholesterol levels significantly when given for 4 weeks (short term). Both powdered sevelamer carbonate and calcium acetate are equally effective in lowering serum phosphorus. Both are well tolerated. Hence, it can be used as an alternative to calcium based PBs in lowering phosphorus levels in Indian population. Moreover, the powdered form has its own advantages with patients who have difficulty chewing and swallowing.
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